9. Abiomed
R&D spending: $75,297,000
Percentage of revenues: 12.7%
2018 overall revenue ranking: 77
Abiomed (Danvers, Mass.) touts its Impella heart pump — a support system of percutaneous, catheter-based devices that offer hemodynamic support to the heart.The Impella 2.5 enables protected PCI procedures. The heart pump pulls blood from the left ventricle through an inlet area near the tip and expels the blood from the catheter into the ascending aorta, according to Abiomed. The device is inserted through a standard catheterization procedure through the femoral artery and into the ascending aorta across the valve and into the left ventricle.
Impella CP is a heart pump that pulls blood from the left ventricle through an inlet area near the tip and expels blood from the catheter into the ascending aorta. The Impella CP is inserted the same way as the Impella 2.5.
Abiomed’s Impella 5.0 delivers up to 5.0L/min of forward blood flow from the left ventricle. It is an intravascular microbial blood pump that is inserted into the left ventricle through femoral cut down or through the axillary artery and goes through the ascending artery and across the valve and into the left ventricle.
The Impella RP is a heart pump that delivers blood from the inlet area that sits in the inferior vena cava, according to Abiomed, through the cannula to the outlet opening near the tip of the catheter in the pulmonary artery. The pump is then inserted through a standard catheterization procedure through the femoral vein and into the right atrium and across the tricuspid and pulmonic valves and into the pulmonary artery. It is designed for right heart support.